Valbiotis shares climbed on Tuesday following the presentation of the full results of a Phase II/III study demonstrating the efficacy of its plant substance Totum.63 against pre-diabetes and the early stages of type 2 diabetes.

After six months of testing, supplementation with Totum.63 at 5 g/day, in two doses, significantly reduced fasting blood glucose, two-hour blood glucose and glycated hemoglobin, the main markers assessed clinically, compared with placebo.

This combination of five plant extracts also significantly reduced progression to type 2 diabetes, with a relative reduction of 40% in new cases of type 2 diabetes at the end of the study compared with placebo.

The complete data from the Reverse-It study published yesterday are very encouraging", judged analysts at Invest Securities, who raised their target price from 12.3 to 13 euros, while reiterating their buy recommendation.

The share price rose by 7.7% around 2:20 pm on this announcement, while the Paris market fell by 0.2%.

Copyright (c) 2023 CercleFinance.com. All rights reserved.